drugset / Trial / NCT03208790
Clinical and Immunohisochemical Evaluation of Chemopreventive Effect of Thymoquinone on Oral Potentially Malignant Lesions.
RandomizedParallel-groupTriple-blindTreatment
Summary
The present randomized, controlled, parallel-grouped trial includes 48 patients (aged 18 to 75 years) suffering from oral potential premalignant lesions. Patients will be randomly assigned into 3 equal groups: Group A: Nigella Sativa buccal tablets group 10mg Group B: Nigella Sativa buccal tablets 5 mg Group C:Control group (placebo)
Timeline
- Start
- 2017-09-30
- Primary completion
- 2020-03-12
- Completion
- 2020-03-12
Publications
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Thymoquinone | Small molecule | 5 mg | Other |
| Subject | Thymoquinone | Small molecule | 10 mg | Other |